{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:33:24Z","timestamp":1761708804204},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2012,9,13]],"date-time":"2012-09-13T00:00:00Z","timestamp":1347494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00292-012-1682-9","type":"journal-article","created":{"date-parts":[[2012,9,11]],"date-time":"2012-09-11T03:23:31Z","timestamp":1347333811000},"page":"273-277","source":"Crossref","is-referenced-by-count":6,"title":["Translationale Forschung und Diagnostik bei GIST"],"prefix":"10.1007","volume":"33","author":[{"given":"E.","family":"Wardelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,13]]},"reference":[{"key":"1682_CR1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577\u2013580","journal-title":"Science"},{"key":"1682_CR2","doi-asserted-by":"crossref","first-page":"v98","DOI":"10.1093\/annonc\/mdq208","volume":"21","author":"Casali","year":"2010","unstructured":"Casali P, Blay J, Experts ECECPo (2010) Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v98\u2013102","journal-title":"Ann Oncol"},{"key":"1682_CR3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"Blanke","year":"2008","unstructured":"Blanke C, Rankin C, Demetri G et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Onkol 26:626\u2013632","journal-title":"J Clin Onkol"},{"key":"1682_CR4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","volume":"42","author":"Debiec-Rychter","year":"2006","unstructured":"Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093\u20131103","journal-title":"Eur J Cancer"},{"key":"1682_CR5","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","volume":"373","author":"Dematteo","year":"2009","unstructured":"Dematteo R, Ballman K, Antonescu C et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097\u20131104","journal-title":"Lancet"},{"key":"1682_CR6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"Joensuu","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor. A randomized trial. JAMA 307:1265\u20131272","journal-title":"JAMA"},{"key":"1682_CR7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","volume":"23","author":"Miettinen","year":"2006","unstructured":"Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 23:70\u201383","journal-title":"Semin Diagn Pathol"},{"key":"1682_CR8","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/bjs.7222","volume":"97","author":"Hohenberger","year":"2010","unstructured":"Hohenberger P, Ronellenfitsch U, Oladeji O et al (2010) Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 97:1854\u20131859","journal-title":"Br J Surg"},{"key":"1682_CR9","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.humpath.2008.06.025","volume":"39","author":"Joensuu","year":"2008","unstructured":"Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39:1411\u20131419","journal-title":"Hum Pathol"},{"key":"1682_CR10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(09)70242-6","volume":"10","author":"Gold","year":"2009","unstructured":"Gold J, G\u00f6nen M, Guti\u00e9rrez A et al (2009) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 10:1045\u20131052","journal-title":"Lancet Oncol"},{"key":"1682_CR11","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/PAS.0b013e3181ef7431","volume":"34","author":"Rossi","year":"2010","unstructured":"Rossi S, Gasparotto D, Toffolatti L et al (2010) Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol 34:1480\u20131491","journal-title":"Am J Surg Pathol"},{"key":"1682_CR12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00292-009-1270-9","volume":"31","author":"Wardelmann","year":"2010","unstructured":"Wardelmann E, Hohenberger P, Reichardt P et al (2010) Gastrointestinal stromal tumors of the stomach. Updates and differences compared to other locations. Pathologe 31:195\u2013198","journal-title":"Pathologe"},{"key":"1682_CR13","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.11323","volume":"106","author":"Wardelmann","year":"2003","unstructured":"Wardelmann E, Losen I, Hans V et al (2003) Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106:887\u2013895","journal-title":"Int J Cancer"},{"key":"1682_CR14","first-page":"3329","volume":"9","author":"Antonescu","year":"2003","unstructured":"Antonescu C, Sommer G, Sarran L et al (2003) Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9:3329\u20133337","journal-title":"Clin Cancer Res"},{"key":"1682_CR15","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/labinvest.3700122","volume":"84","author":"Lasota","year":"2004","unstructured":"Lasota J, Dansonka-Mieszkowska A, Sobin L, Miettinen M (2004) A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 84:874\u2013883","journal-title":"Lab Invest"},{"key":"1682_CR16","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/annonc\/mdq047","volume":"21","author":"Martin-Broto","year":"2010","unstructured":"Martin-Broto J, Gutierrez A, Garcia-del-Muro X et al (2010) Prognostic time dependence of deletions affecting codons 557 and\/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 21:1552\u20131557","journal-title":"Ann Oncol"},{"key":"1682_CR17","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1470-2045(10)70222-9","volume":"11","author":"Le","year":"2010","unstructured":"Le Cesne A, Ray-Coquard I, Bui B et al (2010) Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11:942\u2013949","journal-title":"Lancet Oncol"},{"key":"1682_CR18","doi-asserted-by":"crossref","first-page":"10006","DOI":"10.1200\/jco.2010.28.15_suppl.10006","volume":"28","author":"Corless","year":"2010","unstructured":"Corless C, Ballman K, Antonescu C et al (2010) Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol 28:10006","journal-title":"J Clin Oncol"},{"key":"1682_CR19","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1002\/ijc.26234","volume":"129","author":"Eisenberg","year":"2011","unstructured":"Eisenberg B, Trent J (2011) Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer 129:2533\u20132542","journal-title":"Int J Cancer"},{"key":"1682_CR20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"Corless","year":"2011","unstructured":"Corless C, Barnett C, Heinrich M (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 11:865\u2013878","journal-title":"Nat Rev Cancer"},{"key":"1682_CR21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-med-043010-091813","volume":"63","author":"Joensuu","year":"2012","unstructured":"Joensuu H, DeMatteo R (2012) The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med 63:247\u2013258","journal-title":"Annu Rev Med"},{"key":"1682_CR22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/path.2382","volume":"216","author":"Liegl","year":"2008","unstructured":"Liegl B, Kepten I, Le C et al (2008) Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216:64\u201374","journal-title":"J Pathol"},{"key":"1682_CR23","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s00280-010-1513-8","volume":"67","author":"Wang","year":"2011","unstructured":"Wang W, Conley A, Reynoso D et al (2011) Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 67:S15\u201324","journal-title":"Cancer Chemother Pharmacol"},{"key":"1682_CR24","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1158\/1078-0432.CCR-06-1749","volume":"12","author":"Wardelmann","year":"2006","unstructured":"Wardelmann E, Biermann K, Merkelbach-Bruse S et al (2006) Polyclonal Resistance in Gastrointestinal Stromal Tumor Treated with Sequential Kinase Inhibitors. Clin Cancer Res 12:6206","journal-title":"Clin Cancer Res"},{"key":"1682_CR25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(05)70097-8","volume":"6","author":"Wardelmann","year":"2005","unstructured":"Wardelmann E, Thomas N, Merkelbach-Bruse S et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumors caused by multiple KIT mutations. Lancet Oncol 6:249\u2013251","journal-title":"Lancet Oncol"},{"key":"1682_CR26","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria S et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753\u20131759","journal-title":"J Clin Oncol"},{"key":"1682_CR27","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1158\/1078-0432.CCR-11-2230","volume":"18","author":"Miranda","year":"2012","unstructured":"Miranda C, Nucifora M, Molinari F et al (2012) KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18:1769\u20131776","journal-title":"Clin Cancer Res"},{"key":"1682_CR28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/gcc.20589","volume":"47","author":"Agaram","year":"2008","unstructured":"Agaram N, Wong G, Guo T et al (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47:853\u2013859","journal-title":"Genes Chromosomes Cancer"},{"key":"1682_CR29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/jcp.2009.064550","volume":"62","author":"Agaimy","year":"2009","unstructured":"Agaimy A, Terracciano L, Dirnhofer S et al (2009) V600E BRAF mutations are alternative early molecular events in a subset of KIT\/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 62:613\u2013616","journal-title":"J Clin Pathol"},{"key":"1682_CR30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2011.07.029","volume":"312","author":"Daniels","year":"2011","unstructured":"Daniels M, Lurkin I, Pauli R et al (2011) Spectrum of KIT\/PDGFRA\/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett 312:43\u201354","journal-title":"Cancer Lett"},{"key":"1682_CR31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ajmg.10235","volume":"108","author":"Carney","year":"2002","unstructured":"Carney J, Stratakis C (2002) Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Gen 108:132\u2013139","journal-title":"Am J Med Gen"},{"key":"1682_CR32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1073\/pnas.1009199108","volume":"108","author":"Janeway","year":"2011","unstructured":"Janeway KA, Kim YS, Lodish M et al (2011) Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 108:314\u2013318","journal-title":"Proc Natl Acad Sci USA"},{"key":"1682_CR33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0748-7983(98)91693-6","volume":"24","author":"deJong","year":"1998","unstructured":"deJong E, Mulder W, Nooitgedacht E et al (1998) Carney\u2019s triad. Eur J Surg Oncol 24:147\u2013149","journal-title":"Eur J Surg Oncol"},{"key":"1682_CR34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2796.2009.02110.x","volume":"266","author":"Stratakis","year":"2009","unstructured":"Stratakis C, Carney J (2009) The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med 266:43\u201352","journal-title":"J Intern Med"},{"key":"1682_CR35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PAS.0b013e3181c20f4f","volume":"34","author":"Zhang","year":"2010","unstructured":"Zhang L, Smyrk T, Young WJ et al (2010) Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol 34:53\u201364","journal-title":"Am J Surg Pathol"},{"key":"1682_CR36","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1158\/1078-0432.CCR-08-0533","volume":"14","author":"Dewaele","year":"2008","unstructured":"Dewaele B, Wasag B, Cools J et al (2008) Activity of dasatinib, a dual SRC\/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRA D842V mutation. Clin Cancer Res 14:5749\u20135758","journal-title":"Clin Cancer Res"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-012-1682-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-012-1682-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-012-1682-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T14:14:28Z","timestamp":1562163268000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-012-1682-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,13]]},"references-count":36,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["1682"],"URL":"https:\/\/doi.org\/10.1007\/s00292-012-1682-9","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,13]]}}}